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Abstract
Aims: Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive motor deficits and
degeneration of dopaminergic neurons. Caused by a number of genetic and environmental factors,
mitochondrial dysfunction and oxidative stress play a role in neurodegeneration in PD. By selectively knocking
out mitochondrial transcription factor A (TFAM) in dopaminergic neurons, the transgenic MitoPark mice
recapitulate many signature features of the disease, including progressive motor deficits, neuronal loss, and
protein inclusions. In the present study, we evaluated the neuroprotective efficacy of a novel mitochondrially
targeted antioxidant, Mito-apocynin, in MitoPark mice and cell culture models of neuroinflammation and
mitochondrial dysfunction.
Results: Oral administration of Mito-apocynin (10 mg/kg, thrice a week) showed excellent central nervous
system bioavailability and significantly improved locomotor activity and coordination in MitoPark mice.
Importantly, Mito-apocynin also partially attenuated severe nigrostriatal degeneration in MitoPark mice.
Mechanistic studies revealed that Mito-apo improves mitochondrial function and inhibits NOX2 activation,
oxidative damage, and neuroinflammation.
Innovation: The properties of Mito-apocynin identified in the MitoPark transgenic mouse model strongly
support potential clinical applications for Mito-apocynin as a viable neuroprotective and antineuroinflammatory drug for treating PD when compared to conventional therapeutic approaches.
Conclusion: Collectively, our data demonstrate, for the first time, that a novel orally active apocynin derivative
improves behavioral, inflammatory, and neurodegenerative processes in a severe progressive dopaminergic
neurodegenerative model of PD. Antioxid. Redox Signal. 27, 1048–1066.
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Introduction
Parkinson's disease (pd) is a debilitating neurodegenerative disorder, affecting millions of people worldwide and
is triggered by a complex interplay of genetic and environmental factors. PD neuropathology is characterized by
a loss of dopaminergic neurons in the substantia nigra (SN), loss of dopamine (DA) in the striatum, and
accumulation of abnormal α-synuclein protein, a major constituent of Lewy bodies and Lewy neurites (63).
Motor symptoms such as bradykinesia, tremor, rigidity, and postural instability are still used to clinically
diagnose PD. Although it is known that neuronal loss leads to DA deficiency and motor dysfunction, less is
understood regarding the mechanisms underlying the loss of SN neurons (55). Neuroinflammation, oxidative
stress, and mitochondrial dysfunction have all been implicated in PD pathogenesis (65, 68). Although
mitochondrial dysfunction is well established as an overriding pathophysiological indication of PD, no effective
treatment options are available to improve the efficiency of mitochondrial function in PD.

Innovation
Advances in drug discovery for neurodegenerative diseases have been hampered by the lack of models
that recapitulate the chronic, progressive neurodegeneration characteristic of Parkinson's disease (PD).
However, a recently developed genetic model of mitochondrial dysfunction, known as MitoPark mice,
mirrors many key features of PD. Recently, we developed a new class of pharmacological agents to
effectively dampen the major pathophysiological processes associated with PD (19). The properties of

Mito-apocynin identified in this model strongly support potential clinical applications for Mito-apocynin
as a viable neuroprotective and antineuroinflammatory drug for treating PD when compared to
conventional therapeutic approaches.
Mitochondrial toxin-based PD models such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6hydroxydopamine (6-OHDA), and rotenone are used to screen compounds for further development. However,
toxin-based PD models do not reflect human PD mainly due to the acute nature of neuronal injury,
toxicant/drug interactions, and between-subject response variation (6, 21, 47). MitoPark mice were created by
selective inactivation of mitochondrial transcription factor A (TFAM) in the nigrostriatal pathway (22). Key
pathological features of PD such as adult onset, progressive neurodegeneration, protein inclusions, and
progressive motor deficits ameliorated by l-3,4-dihydroxyphenylalanine (l-DOPA) have been identified in
MitoPark mice (27), making the model ideal for testing novel mitochondria-targeted neuroprotective agents.
A strong therapeutic potential exists for mitochondria-targeted antioxidants (MTAs) in neurodegenerative
disorders (39). We recently demonstrated that apocynin (4-hydroxy-3-methoxyacetophenone), a plant-derived
molecule structurally related to vanillin, and its dimer, diapocynin, are neuroprotective in the MPTP and
LRRK2R1441G mouse models (18, 32). As an inhibitor of NOX2 activity, apocynin has been studied in various cell
culture and animal models of PD (1, 12, 28). Although the high doses of apocynin and diapocynin (300 mg/kg)
used in these animal studies were well tolerated, more efficacious apocynin analogs are needed. We therefore
synthesized a series of mitochondria-targeted apocynins (conjugated to a triphenylphosphonium cation moiety
via an alkyl chain with differing chain lengths [C2-C11 carbon atoms]). Using Mito-apo-C2, we have recently
established that Mito-apo protected against neuroinflammation and neurodegeneration in the MPTP model
(33). Herein, we evaluated the disease-modifying efficacy of a long-acting Mito-apo-C11 in the MitoPark model
that recapitulates key features of PD, including mitochondrial dysfunction, microglial activation, and
dopaminergic degeneration. Our results show that oral administration of Mito-apo dampens chronic,
progressive behavioral deficits and dopaminergic neurodegeneration. Additional mechanistic studies support
the enhanced mitochondrial function and anti-inflammatory properties of Mito-apo.

Results
Mito-apo restores mitochondrial function in dopaminergic neuronal cells
We first assessed the effect of Mito-apo on key markers of mitochondrial bioenergetics of dopaminergic
neuronal cells. The Seahorse extracellular flux analyzer revealed the basal respiration rate to be nearly double
the control oxygen consumption rate (OCR) values in 10- to 30-μM Mito-apo-treated N27 dopaminergic
neuronal cells (Fig. 1A, B). On treatment with oligomycin, Mito-apo-treated cells showed a significantly higher
ATP-linked respiration (Fig. 1A, C) and respiratory capacity (Fig. 1A, D) than untreated cells. As expected, in the
positive control, 1 μM rotenone abolished the OCR signal (Fig. 1A–D).

FIG. 1. Bioenergetics and in vitro characterization of Mito-apo. (A–D) N27 cells given 10–30 μM Mito-apo for
3 h were measured using a Seahorse XF96 analyzer. Basal respiration rate before injection (A, B). After adding
oligomycin, ATP-linked respiration (A, C). Respiratory capacity measured as OCR after carbonilcyanide ptrifluoromethoxyphenylhydrazone (FCCP) injection (A, D). (E–G) Mito-apo replenished ATP
levels, (E) upregulated m-aconitase activity, (F) and decreased oxidant production in TFAM KD cells (TFAM-KD).
TFAM-KD and control cells were incubated with 10–30 μM Mito-apo for 3 (E–F) or 12 h (G). Raw luminescence
units of ATP produced (E). Aconitase activity (F) and mitochondrial ROS production (G) as determined by
aconitase and MitoSOX assays. (H–J) TFAM-KD and control cells were incubated with 10–30 μM Mito-apo for
12 h, and mitochondria were stained by MitoTracker (scale bar = 10 μm). Analysis of mitochondrial length (I) and
degree of circularity (J). Rotenone (1 μM) was used as a positive control in all experiments. Graphical results
represented as the mean ± SEM (n = 6 wells/group). **p < 0.01 versus control;
***p < 0.001 versus control; #p < 0.05 versus vehicle-treated TFAM-KD cells. See also Supplementary Figures
S1 and S6. KD, knockdown; OCR, oxygen consumption rate; ROS, reactive oxygen species; SEM, standard error of
the mean; TFAM, mitochondrial transcription factor A.
Given that knockdown (KD) of TFAM has been shown to result in cellular ATP depletion and loss of
mitochondrial function in mammalian cell culture studies (48), we determined if Mito-apo could improve
mitochondrial function in stable TFAM-KD N27 cells that we generated using the CRISPR/Cas9 system as

described in Supplementary Data (Supplementary Data are available online at www.liebertpub.com/ars).
Transduction of N27 cells with TFAM-KD resulted in >80% loss in TFAM mRNA levels relative to control cells
(Supplementary Fig. S1). In contrast to control N27 cells, TFAM-KD cells had significantly lower cellular ATP levels
(Fig. 1E). Rotenone (1 μM) for 3 h (positive control) dramatically decreased cellular ATP levels in control N27
cells. Mito-apo did not significantly alter the ATP levels in control cells. However, exposure to 10–30 μM Mitoapo for 3 h dramatically increased cellular ATP levels in TFAM-KD N27 cells, suggesting that Mito-apo replenishes
ATP levels in mitochondrially stressed cells.
Aconitases are iron–sulfur-containing enzymes that isomerize citrate and are inactivated during mitochondrial
oxidative stress. Measurement of aconitase enzyme activity in TFAM-KD cells revealed significantly decreased maconitase activity when compared to control N27 cells, indicating that TFAM-KD led to significant mitochondrial
oxidative damage (Fig. 1F). However, treating the TFAM-KD cells with 10–30 μM Mito-apo for 3 h returned maconitase activity to levels present in control N27 cells. Mito-apo did not significantly alter the m-aconitase
activity in control cells, and rotenone strongly reduced m-aconitase activity in both cells (Fig. 1F).
We also assessed the loss of mitochondrial function with MitoSOX™ red dye in TFAM-KD and control N27 cells.
Basal oxidation of MitoSOX probe was significantly higher in TFAM-KD than in control cells (Fig. 1G). A 12-h
exposure to 10 and 30 μM Mito-apo decreased the rate of probe oxidation in TFAM-KD, but not in control N27
cells (Fig. 1G). As observed previously using hydroethidine probe in control N27 cells (20), rotenone strongly
stimulated MitoSOX oxidation in both cell lines.
MitoTracker red dye was used to visualize integrity or structural abnormalities in TFAM-KD N27 cells. Healthy
mitochondria, such as those from control cells, appear as long, thread-like structures (Fig. 1H). Relative to those
of control cells, the mitochondria of TFAM-KD N27 cells were significantly shorter (Fig. 1I) and more circular (Fig.
1J), further indicating a striking loss of mitochondrial structural integrity. Although 10 μM Mito-apo was not
enough to improve mitochondrial morphology, TFAM-KD cells treated with 30 μM Mito-apo exhibited
significantly increased mitochondrial length (Fig. 1H, I). Collectively, results from these experiments suggest that
Mito-apo restores mitochondrial morphology and function in TFAM-KD N27 cells.

Mito-apo stalls progression of motor deficits
Considering that Mito-apo was capable of replenishing mitochondrial function in TFAM-KD N27 cells, we decided
to determine if Mito-apo is neuroprotective in the MitoPark mouse model of PD, in which TFAM is selectively
inactivated in dopaminergic neurons. Preceded by early neurochemical alterations, these mice exhibit
behavioral deficits by 12 weeks, which become progressively worse by 24 weeks (34). Our dose for this study
was initially based on the severity of our model and the therapeutic efficacy reported for other model systems in
previous publications (19, 33). Given that MitoPark is one of the most severe models of PD, we considered that
the lower dose of Mito-apocynin used in the MPTP article (3 mg/kg/day) and LRRK2 article (3 mg/kg, 3 × /week)
might not be sufficient in the MitoPark mice, and therefore used a higher dose. As depicted in our treatment
paradigm (Fig. 2A), MitoPark and age-matched C57 mice were orally administered either Mito-apo (10 mg/kg,
3 × /week) or vehicle (10% ethanol/PBS) beginning at age 13 weeks. Open-field activity and rotarod behavioral
performances were evaluated at ages 18, 21, and 24 weeks (Supplementary Fig. S2).

FIG. 2. Progressive motor deficits in MP mice are improved with Mito-apo. (A) Treatment schedule showing
C57 and MP mice orally administered vehicle or Mito-apo (10 mg/kg). (B) VersaPlot showing horizontal activity
and rearing activity (red dots) during a 10-min open-field test. Horizontal (C) and vertical (D) activities and
distance traveled (E) during open-field test. (F) Time spent on rotarod. Graphical results represented as the
mean ± SEM (n = 9–13 mice/group). **p < 0.01 versus control;
***p < 0.001 versus control; ###p < 0.001 versus vehicle-treated MP. See also Supplementary Figure S2. MP,
MitoPark.
Decreased movement, as expected in 24-week MitoPark mice, is shown by representative Versaplot maps (Fig.
2B), and improved locomotion can be seen in plots of the Mito-apo-treated MitoPark mice. Consistently, 24week MitoPark mice exhibited decreased horizontal activity (Fig. 2C), vertical activity (Fig. 2D), total distance
traveled (Fig. 2E), and time spent on the rotarod (Fig. 2F). Mito-apo treatment did not have any significant effect
on any of these behavioral parameters in age-matched control mice, but importantly, the horizontal and vertical
activity levels and rotarod performance of MitoPark mice were significantly retained by Mito-apo treatment in
contrast to vehicle-treated MitoPark mice.

Mito-apo treatment dampens nigrostriatal tyrosine hydroxylase neuronal loss and
striatal DA depletion
Neurodegeneration in the SN is progressive and severe in aged MitoPark mice (27). Brain sections from 24-week
MitoPark mice were immunostained for tyrosine hydroxylase (TH) to detect dopaminergic neurons. A significant

loss of TH+ cell bodies and terminals in the SN and striatum, respectively, occurred in vehicle-treated 24-week
MitoPark mice (middle panel) in contrast to vehicle-treated age-matched C57 mice (top panel) (Fig. 3A). DAB
immunostaining showed significantly higher levels of TH immunoreactivity (Fig. 3A) and neuronal counts (Fig.
3B) in the striatum and SN of Mito-apo-treated MitoPark mice compared to vehicle-treated MitoPark mice.
Mito-apo did not alter the number of TH neurons in control mice. Further confirmation came from Western
blots and their densitometric analysis, where higher levels of TH protein expression were observed in the SN of
Mito-apo-treated MitoPark mice versus vehicle-treated MitoPark mice (Fig. 3C). Full Western blots from cropped
images in all figures can be found in Supplementary Fig. S3.

FIG. 3. Neurodegeneration and dopamine depletion in MP mice are attenuated by Mito-apo. DAB
immunostaining (A) in striatum and SN (scale bars = 1 mm and 100 μm) of vehicle-treated C57 (top), vehicletreated MP (middle), and Mito-apo-treated MP mice (bottom). (B) Stereological cell counts of TH+ neurons in the
SN of n = 3/group. (C) Representative Western blot of two animals/group and densitometric analysis of TH
protein levels normalized to β-actin in the SN (n = 6/group). High-performance liquid chromatography with
electrochemical detection was used for determination of dopamine (D), DOPAC (E), and HVA (F). Graphical
results represented as the mean ± SEM (n = 6–8 mice/group). ***p < 0.001 versus vehicle-treated C57; #p < 0.05,
or ###p < 0.001 versus vehicle-treated MP. DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; SN,
substantia nigra; TH, tyrosine hydroxylase.
Since Mito-apo-treated MitoPark mice had more dopaminergic neurons remaining in the SN, we performed
high-performance liquid chromatography (HPLC) with electrochemical detection to determine if striatal levels of
DA and its metabolites were also protected. We observed a severe loss of DA, DOPAC, and HVA, respectively, in
the striatum of vehicle-treated MitoPark mice compared to age-matched control mice (Fig. 3D–F). In contrast,
Mito-apo increased DA and DOPAC by 2.6- and 2.0-fold, respectively, when compared to vehicle-treated
MitoPark mice. Mito-apo did not affect striatal DA and its metabolite levels in C57 black mice. Together, these

data suggest that Mito-apo substantially increases the TH neuronal cell count and striatal DA levels in aged
MitoPark mice.

Mito-apo attenuates mitochondrial aconitase inactivation and oxidative damage
To further determine the effect of Mito-apo on mitochondrial redox status in the MitoPark model, we used ex
vivo electron paramagnetic resonance (EPR) analysis to see if Mito-apo protects against inactivation of
mitochondrial aconitase. Previously, we had shown that Mito-Q10 treatment mitigates MPTP-mediated
inactivation of mitochondrial aconitase and inhibits the increase in the EPR signal intensity at g′ = 6 (attributed
to cytochrome c) detected in brain tissues obtained from MPTP-treated mice (31). Similarly, in this study, we
show that the EPR spectra in the g ∼ 2 region (blue bracket, Fig. 4A) from MitoPark striatal samples (middle
spectra, Fig. 4B) have higher fractional intensities, which are primarily due to the inactive, oxidized [3Fe–
4S]+ cluster of aconitase. EPR spectral signals were internally normalized to high-spin heme (blue arrow, Fig. 4A,
C). A similar trend occurred in cortical tissues, but was insignificant (Supplementary Fig. S4). Most importantly,
Mito-apo treatment significantly reduced the fractional intensities from the [3Fe–4S]+ cluster signal in MitoPark
mice relative to vehicle treatment (Fig. 4D).

FIG. 4. Mitochondrial aconitase inactivation and oxidative stress are attenuated in Mito-apo-treated MP mice.
(A) The g ∼ 2 region (blue bracket) and HS heme (arrow, internal control) of the experimental EPR spectra from
the pooled striatum (each spectrum represents 3–5 combined animal tissues) from vehicle-treated C57 (top),
vehicle-treated MP (middle), and MP mice treated with 10 mg/kg Mito-apo from 13 to 24 weeks of age

(bottom). The spectra are primarily due to the oxidized [3Fe–4S] cluster of aconitase (∼3330 G), and the reduced
N2 (3370 G), N4 (3485 G), and N3 (3540 G) complex I iron–sulfur complexes, although other components
underlie these species, and fits to all components were used to estimate the relative contributions to the
spectra (fits are presented under each of the three experimental traces, respectively, in A). (B) Expansion of
the g ∼ 2 region. Fractional intensities from EPR spectra in the g ∼ 2 region normalized to combined tissue
weight (C) and internally normalized to the HS-heme group (D). (E) Twenty-four-week mouse tissues of vehicletreated C57 (top), vehicle-treated MP (middle), and Mito-apo-treated MP mice (bottom) were double
immunostained for TH and 4-HNE (scale bar = 10 μm). Merged MP image shows colocalization of TH and 4-HNE
in DAergic neurons. (F) Representative Western blot and densitometric analysis of 4-HNE protein in the SN
(n = 6/group). *p < 0.05 versus C57; #p < 0.05 versus vehicle-treated MP. See also Supplementary Figure S4. EPR,
electron paramagnetic resonance; 4-HNE, 4-hydroxynonenal.
Oxidative damage biomarkers such as nitrotyrosine-containing proteins and lipid peroxidation product 4hydroxynonenal (4-HNE) have been shown in animal models of PD and have high correlation to disease states
(32, 51). Confocal imaging of immunohistochemistry (IHC) double labeled with TH antibody and Western blot
analysis revealed increased 4-HNE expression in the SN of aged MitoPark mice but not in control mice (Fig. 4E,
F). Mito-apo administration almost completely suppressed 4-HNE levels in the SN of aged MitoPark mice. These
results demonstrate that Mito-apo attenuates mitochondrial aconitase inactivation in the striatum and oxidative
damage in nigral neurons of aged MitoPark mice.

Mito-apo inhibits microglia activation in the SN
Neuroinflammation is now recognized to play a key role in dopaminergic neurodegeneration in human PD
patients and in mouse models (17, 53, 66). Although mitochondrial dysfunction and oxidative stress act as key
players in the progressive degenerative MitoPark mouse model, the presence of neuroinflammation in this
model has not yet been explored. Western blotting and DAB immunostaining show that IBA1 expression
increases in the SN of MitoPark mice (Fig. 5A, B). However, levels of the IBA1 protein were significantly lower in
Mito-apo-treated MitoPark mice. IBA1 DAB immunostaining (Fig. 5B) revealed an increased number of microglia
in the aged, vehicle-treated MitoPark SN, and at higher magnification, increased soma size and fewer processes,
indicating an activated phenotype. These features occurred to a much lesser extent in the Mito-apo-treated
MitoPark mice. Indeed, the cell count per field (Fig. 5C) was significantly lower in the Mito-apo-treated group,
average soma size was smaller (Fig. 5D), and ImageJ skeleton analysis revealed more process endpoints per cell
in Mito-apo-treated MitoPark mice when compared to vehicle-treated MitoPark mice (Fig. 5E). Other variables
indicative of a normal microglia phenotype, such as the number of branches, number of junctions, and the
longest-shortest path, were significantly reduced in the MitoPark group when compared to controls (Fig. 5F–H).
However, the MitoPark mice treated with Mito-apo did not exhibit significant microglial morphological changes
when compared to age-matched control mice. We also observed CD68+ staining, a marker of microglia
activation, in vehicle-treated MitoPark mice that was not present in control or Mito-apo-treated MitoPark mice
(Supplementary Fig. S5).

FIG. 5. Mito-apo inhibits microglia activation in the SN of MP mice. (A) Western blot and densitometric analysis
of IBA1 protein in the SN (n = 6/group). (B) IBA1 DAB immunostained sections from 24-week mouse SN of
vehicle-treated C57 (left), vehicle-treated MP (middle), and Mito-apo-treated MP mice (right) showing microglia
morphology (scale bar = 200 μm). ImageJ analysis of microglia for cells per field (C), soma size (D), number of
endpoints per cell (E), number of branches per cell (F), number of junctions per cell (G), and longest-shortest
path (H). Graphical results represented as the mean ± SEM (n = 5–7 mice/group). *p < 0.05 versus C57 control;
**p < 0.01, ***p < 0.001 versus vehicle-treated C57; #p < 0.05 versus vehicle-treated
MP; ##p < 0.01 versus vehicle-treated MP; ###p < 0.001 versus vehicle-treated MP. See also Supplementary Figure
S5.

Mito-apo decreases NOX2 and iNOS activity in microglia
An increase in NOX2 and iNOS expression during microglial activation may synergistically contribute to neuronal
death (46). Since Mito-apo treatment inhibits microglia activation, we then tested whether it also dampened
NOX2 activity and iNOS induction. Immortalized microglial cells were generated as described in the Materials
and Methods section and obtained as a kind gift from Dr. Douglas Golenbock for conducting the following
experiments (37). To better define the therapeutic target of Mito-apo in microglia, we examined NOX2
activation by p47phox translocation from cytosol to the membrane. Western blot analysis revealed that
lipopolysaccharide (LPS) robustly increased the amount of membrane-bound p47phox in microglia, while the
cytosolic p47phox was significantly reduced when compared to control cells (Fig. 6A). Furthermore, this is
substantiated by immunocytochemical results showing increased colocalization of p47phox with cholera toxin
subunit B (CTXB-555), a membrane marker, following LPS treatment (Fig. 6B). LPS-stimulated microglia cotreated
with Mito-apo showed a significant decrease in membrane p47phox and an increase in cytosolic p47phox when
compared to vehicle-treated LPS-stimulated microglia (Fig. 6A). Similarly, reduced colocalization of p47phox and

CTXB-555 was observed in Mito-apo-treated LPS-stimulated microglia (Fig. 6B). Together, these data suggest
that Mito-apo can effectively prevent p47phox membrane recruitment, which is otherwise obligatory for NOX2
activation.

FIG. 6. Mito-apo decreases NOX2 and iNOS activity in microglia. (A) Western blot and accompanying
densitometric analysis of membrane and cytosolic fractions from control and LPS-stimulated microglia treated
with or without 10 μM Mito-apo. (B) Immunocytochemistry revealing increased membrane colocalization of
p47phox upon LPS stimulation that is reduced with Mito-apo treatment. CTXB = cholera toxin subunit B with 555
fluorophore. (C) ATRA-differentiated HL60 cells were pretreated with Mito-apo for 30 min in HBSS
supplemented with HEPES buffer (25 mM, pH 7.4) and DTPA (0.1 mM), followed by the addition of the probe
and PMA (1 μM). The slope of the fluorescence intensity monitored over 2 h was used to measure the probe
oxidation rate. (D) Nitric oxide production from microglia as estimated in supernatant by Griess assay of nitrite
levels. (E) LPS-induced oxidation of o-MitoPhB(OH)2 to o-MitoPhOH in microglia was inhibited by Mitoapo. (F) Luminex multiplex assay showing levels of TNF-α, IL-1β, IL-6, and IL-12 in supernatant from LPSstimulated microglia (n = 4–6/group). Graphical results represented as the mean ± SEM (n = 3/group).
*p < 0.05 versus C57 control. **p < 0.01, ***p < 0.001 versus control; #p < 0.05, ##p < 0.01, ###p < 0.001 versus LPS.
See also Supplementary Figure S7. ATRA, all-trans retinoic acid; IL, interleukin; LPS, lipopolysaccharide; PMA,
phorbol myristate acetate; TNF-α, tumor necrosis factor α.

Our previous publication shows that HL60 cells differentiated into neutrophils and treated with phorbol
myristate acetate (PMA) can be used as a reliable source of endogenous NOX2 activation (73). To test the effect
of Mito-apo treatment on NOX2 activity in intact cells, we used all-trans retinoic acid (ATRA)-differentiated HL60
cells, stimulated with PMA. We utilized hydropropidine (HPr+) as the probe for NOX2-derived superoxide radical
anion (O2•−) and coumarin boronic acid (CBA) as a probe for hydrogen peroxide (H2O2) (73, 75). The 30-min
pretreatment of cells with a low micromolar concentration (<10 μM) of Mito-apo led to a dose-dependent
inhibition of the PMA-stimulated generation of O2•− and H2O2 (Fig. 6C). This demonstrates that Mito-apo directly
or indirectly mitigates NOX2 activity.
Next, we tested the effect of Mito-apo on oxidant production in microglial cells. After exposing microglial cells to
LPS (1 μg/ml) for 12 h in the presence or absence of Mito-apo (10–30 μM), Griess assay revealed that Mito-apo
completely blocked LPS-induced nitric oxide production (Fig. 6D). In addition, LC-MS-based monitoring of the
conversion of the o-MitoPhB(OH)2 probe into the phenolic product (o-MitoPhOH) (10, 11, 74, 75) indicates
significant suppression of mitochondrial oxidant levels (Fig. 6E). The Mito-apo cotreatment also significantly
attenuated LPS-induced increases in the levels of supernatant cytokines, including tumor necrosis factor α (TNFα), interleukin-1β (IL-1β), IL-12, and IL-6, as measured by Luminex multiplex immunoassay (Fig. 6F). For
comparison, 10 μM vitamin C and 10 μM apocynin were also tested, but neither treatment significantly
attenuated LPS-stimulated neuroinflammation endpoints at this dose (Supplementary Fig. S6).

Mito-apo attenuates iNOS and NOX2 expression in the SN of MitoPark mice
Consistent with our in vitro results, double immunolabeling experiments confirmed that the increased iNOS
expression occurred in IBA1+ microglia and was significantly reduced in Mito-apo-treated MitoPark mice (Fig.
7A). Western blotting revealed an increase in iNOS expression in the SN of 24-week MitoPark mice that was
significantly attenuated in the Mito-apo-treated mice (Fig. 7B). In addition, gp91phox, a subunit of NOX2, was
upregulated in microglia of the SN of aged MitoPark mice (Fig. 7C, D), yet was significantly reduced in the Mitoapo-treated group, as evidenced by Western blotting and IHC double labeling with IBA1.

FIG. 7. Mito-apo inhibits iNOS and NOX2 expression in the SN of MP mice. Determination of NOX2 and iNOS
activity in the SN. (A) Twenty-four-week mouse tissues of vehicle-treated C57 (top), vehicle-treated MP (middle),
and Mito-apo-treated MP mice (bottom) stained for IBA1 and iNOS (scale bar = 10 μm). Merged MP image shows
colocalization (arrow) of IBA1 and iNOS in SN tissues. (B) Representative Western blot and densitometric
analysis of iNOS protein in the SN (n = 6/group). (C) IHC for IBA1 and gp91phox of vehicle-treated C57 (top),
vehicle-treated MP (middle), and Mito-apo-treated MP mice (bottom). Merged MP image shows colocalization
(arrows) of IBA1 and gp91phox in SN tissues. (D) Representative Western blot and densitometric analysis of
gp91phox protein in the SN (n = 6/group). (E) IHC for TH and 3-nitrotyrosine of vehicle-treated C57 (top), vehicletreated MP (middle), and Mito-apo-treated MP mice (bottom). Graphical results represented as the
mean ± SEM. #p < 0.05 versus vehicle-treated MP; *p < 0.05 versus vehicle-treated C57;
***p < 0.001 versus vehicle-treated C57; IHC, immunohistochemistry.
Given that the NOX4 isoform has been shown to localize in the mitochondria of neurons (7), we also assessed
whether Mito-apo alters NOX4 in our mitochondrially defective cell and animal models of PD. In TFAM-KD N27
dopaminergic cells, NOX4 levels increased significantly when compared to control cells (Supplementary Fig.
S7A). However, Mito-apo treatment did not alter NOX4 levels in TFAM-KD cells. Furthermore, NOX4 mRNA and
protein levels were not altered in the SN of either MitoPark mice or MitoParks treated with Mito-apo when

compared to age-matched control mice (Supplementary Fig. S7B, C). These data suggest that Mito-apo is more
selective for NOX2 over NOX4 in neuronal cells and NOX4 is not a major contributor to oxidative damage in the
MitoPark model.
Peroxynitrite, formed when superoxide reacts with nitric oxide, nitrates tyrosine residues on proteins and
contributes to neuronal cell death (33, 75). Increased nitrative modification was evidenced by higher 3-NT
expression in the SN of 24-week MitoPark mice compared to C57 black mice (Fig. 7E). Notably, 3-NT expression
was significantly suppressed in Mito-apo-treated MitoPark mice. Overall, these data show that Mito-apo
attenuated microglia activation and neuronal cell death in MitoPark mice by suppressing oxidative and nitrative
stress.

Mito-apo is central nervous system bioavailable without systemic adverse effects
Finally, we determined if Mito-apo reaches its target brain tissues, the SN and striatum. Mice were orally
administered Mito-apo (10 mg/kg), sacrificed, and tissues were harvested at 30 min, 3, 6, 12, 24, and 48 h.
Striatal and nigral regions were processed for HPLC. Here, we have provided evidence that Mito-apo reaches its
target brain tissues, the SN and striatum, and did not cause systemic adverse effects (Supplementary Fig.
S8 and Tables 1 and and2).2). LC MS/MS analysis did not detect the Mito-apo in extra-nigral tissues. We also
conducted a dose–response study at the 6-h time point, when Mito-apo availability peaks in brain tissues
(Supplementary Fig. S8), yet did not detect any significant difference between 10 and 30 mg/kg Mito-apo oral
administration.

Table 1. clinical pathology results for mice (n = 3) 3 hour postoral gavage with 10 mg/kg mito-apo-c11 using the abaxis system
Parameter
Albumin
Alkaline phosphatase
ALT
Amylase
Total bilirubin
BUN
Calcium
Phosphorous
Creatinine
Glucose
Sodium
Potassium
Total protein

Units
g/dl
IU/L
IU/L
U/L
U/L
mg/dl
mg/dl
mg/dl
mg/dl
mg/dl
mEq/L
mEq/L
g/dl

p
0.31
1.00
0.41
0.38
0.37
0.83
0.50
0.94
0.37
0.05
0.84
1.00
0.81

3-h Control
Mean
3.23
70.67
65.67
1061.33
0.30
15.33
11.73
10.20
0.27
292.33
159.00
8.50
5.50

3-h Mito-apo-C11
Min
Max
SD
Mean
2.40
3.90
0.62
3.77
56.00 88.00
13.20 70.67
38.00 84.00
19.91 94.00
927.00 1316.00 180.17 1699.00
0.30
0.30
0.00
0.33
12.00 21.00
4.03
14.67
11.50 12.20
0.33
11.50
8.50
12.20
1.53
10.30
<0.20 0.40
0.09
0.20
274.00 317.00 18.12 336.67
156.00 161.00 2.16
159.33
>8.50 >8.50
0.00
8.50
5.40
5.60
0.08
5.53

Min
3.50
63.00
54.00
1050.00
0.30
13.00
11.20
9.50
<0.20
320.00
159.00
>8.50
5.30

Max
4.00
81.00
146.00
2977.00
0.40
16.00
11.90
11.80
<0.20
352.00
160.00
>8.50
5.70

SD
0.21
7.59
38.51
903.72
0.05
1.25
0.29
1.06
0.00
13.10
0.47
0.00
0.17

Table 2. clinical pathology results for mice (n = 3) 48 hour postoral gavage with 10 mg/kg mito-apo-c11

Parameter
Albumin
Alkaline phosphatase
ALT
Amylase
Total bilirubin
BUN
Calcium
Phosphorous
Creatinine
Glucose
Sodium
Potassium

Units
g/dl
IU/L
IU/L
U/L
U/L
mg/dl
mg/dl
mg/dl
mg/dl
mg/dl
mEq/L
mEq/L

p
0.23
0.02
0.20
0.05
0.52
0.15
0.02
0.01
1.00
0.06
0.14
0.37

48-h Control
Mean
4.07
134.00
60.33
858.33
0.37
14.67
10.73
8.30
0.20
227.67
159.00
8.40

Min
3.70
119.00
45.00
816.00
0.30
13.00
10.50
8.10
0.20
196.00
156.00
8.20

Max
4.40
159.00
77.00
935.00
0.40
18.00
11.00
8.50
0.20
250.00
161.00
8.50

SD
0.29
17.80
13.10
54.31
0.05
2.36
0.21
0.16
0.00
23.01
2.16
0.14

48-h Mito-apo-C11
Mean
4.37
82.00
90.33
1024.00
0.33
17.67
11.40
10.03
0.20
271.67
162.00
8.50

Min
4.30
72.00
58.00
962.00
0.30
17.00
11.20
9.40
0.20
261.00
161.00
8.50

Max
4.50
91.00
118.00
1118.00
0.40
18.00
11.60
10.40
0.20
282.00
163.00
8.50

SD
0.09
7.79
24.72
67.59
0.05
0.47
0.16
0.45
0.00
8.58
0.82
0.00

Total protein

g/dl

0.12 5.17

4.90

5.50

0.25

5.53

5.40

5.60

0.09

Clinical pathology can be particularly useful in predicting toxicity in animal models for preclinical evaluation
(5, 59). Blood plasma, collected by cardiac puncture at 3 and 48 h after gavaging mice with 10 mg/kg Mito-apo,
was analyzed using the Abaxis system. Clinical pathology variables are reported in Tables 1 and and2.2. At 3 h,
the only significant difference between vehicle and Mito-apo-treated C57 black mice was blood glucose level
(Table 1). As mice were not fasted, the range of values for both groups is considered acceptable (57). Alkaline
phosphatase (ALP) levels, an indicator of hepatobiliary or bone disease, were significantly less in Mito-apotreated mice than in controls after 48 h (Table 2), but still within normal reference intervals. Calcium and
phosphorous levels were elevated in the Mito-apo-treated group, but no other significant changes were
observed at 48 h postgavage. These results suggest that Mito-apo can rapidly cross the blood–brain barrier and
persist in the central nervous system (CNS) to produce its neuroprotective effect without contributing to any
major acute adverse effects.

Discussion
Oxidative stress, mitochondrial dysfunction, and neuroinflammation contribute to dopaminergic degeneration in
PD (3, 13, 66). Reactive oxygen species (ROS) derived from NOX2 and mitochondria potentiate
neurodegeneration through oxidative stress and promote proinflammatory events (12, 56). In this study, we
tested a recently created pharmacophore, Mito-apo, in cell culture and animal models of mitochondrial
dysfunction and neuroinflammation. First, Mito-apo treatment increased OCR in a dopaminergic cell line,
indicating a bioenergetic effect. This was further clarified by showing that treatment with Mito-apo increased
aconitase activity and ATP levels, improved mitochondrial structural integrity, and decreased mitochondrial
oxidants in TFAM-KD N27 cells. In MitoPark mice, Mito-apo treatment attenuated progressive motor deficits,
striatal neurotransmitter depletion, and nigrostriatal degeneration, suggesting a neuroprotective property.
Mito-apo treatment also prevented microglial activation, proinflammatory mediators, NOX2 and iNOS
activation, and oxidative stress marker formation. Thus, our data demonstrate anti-inflammatory, antioxidant,
and neuroprotective properties of a new apocynin derivative, Mito-apo, in MitoPark mice that possess
pathological features of chronic dopaminergic neurodegeneration, including mitochondrial dysfunction,
oxidative damage, and neuroinflammation.
Mitochondrial dysfunction can be found in toxin-based models, such as the MPTP and 6-OHDA treatment
paradigms, and in genetic models, such as the LRRK2- and PINK1-based models (3, 16, 44, 62, 71). Wang et
al. (69) demonstrated that TFAM inactivation results in respiratory chain deficiency and increased in
vivo apoptosis, and proposed that the resulting loss of mitochondrial function has important therapeutic
implications for human disease. Although the MitoPark model, with TFAM knocked out in the nigrostriatal
pathway, does not mirror any specific genetic mutation associated with PD, both TFAM and mitochondrial DNA
changes have been implicated in aging and PD (2, 29, 30, 54). Similarly, the TFAM-KD N27 dopaminergic cells
generated using the CRISPR/Cas9 system manifested mitochondrial dysfunction as reduced m-aconitase activity
and ATP levels, increased oxidant production, and altered mitochondrial morphology. Our results clearly indicate
that Mito-apo restores functional mitochondria by increasing mitochondrial bioenergetics and inhibiting
production of oxidants. Thus, treatment with an MTA can alleviate the loss of mitochondrial structural and
functional integrity in a cell culture model of mitochondrial dysfunction.
We next determined if Mito-apo exerts its protective action on mitochondrial redox in vivo. To gain insights into
any effect of Mito-apo on oxidative stress amelioration in MitoPark mice, we monitored the EPR signals due to
mitochondrial aconitase iron–sulfur clusters in brain tissue at cryogenic temperatures. ROS-induced oxidation of
the catalytically required [4Fe–4S]2+ cluster inactivates the aconitase enzyme due to loss of the labile iron ion,
forming the EPR detectable [3Fe–4S]+ cluster. Mito-apo treatment significantly inhibited the development of the
[3Fe–4S]+ cluster EPR signal from mitochondrial aconitase in MitoPark mice. These results suggest that Mito-apo

treatment can effectively block m-aconitase inactivation in aged MitoPark mice. Advancing age is a main risk
factor in neurodegenerative disease and is correlated with increased mitochondrial dysfunction and oxidative
stress, leading to irreversible structural changes in proteins, lipids, and DNA (51, 65, 68). Here we found that
levels of 4-HNE-modified proteins, an unsaturated aldehyde generated during lipid peroxidation and marker of
oxidative damage, were significantly higher in the SN of 24-week MitoPark brains compared to age-matched C57
black controls, yet Mito-apo treatment significantly decreased these levels. Hence, oxidative stress associated
with the inherent mitochondrial dysfunction in the MitoPark model can be reduced by long-term, low-dose
treatment with Mito-apo.
In the CNS, microglial activation and the production of proinflammatory factors, including cytokines, ROS, and
RNS, are hallmarks of inflammatory reactions. Our IHC and Western blot analyses revealed significantly
increased IBA1 expression in the SN of 24-week MitoPark mice coupled with increased soma size and fewer
processes, suggesting increased microglia activation in 24-week MitoPark mice. Mito-apo-treated MitoPark mice
had significantly fewer IBA1+ cells, decreased soma size, and increased branching complexity consistent with
ramified microglia when compared to vehicle-treated MitoPark mice. Mito-apo treatment also effectively
decreased iNOS and gp91phox protein levels in the IBA1+ nigral cells of MitoPark mice. Activation of NOX2 and
mitochondrial ROS signaling was proposed to involve crosstalk that increases production of both in a feedforward cycle (15, 46). NOXs play an obvious role in dopaminergic neurodegeneration via ROS generation
(9, 52). However, their involvement in PD is potentially more complex, involving other contributing factors such
as protein aggregation and mitochondrial dysfunction (13, 15, 20). In animal models of PD in which
proinflammatory enzymes are elevated, anti-inflammatory therapies have successfully modulated the
neurodegenerative process (32, 56). Reactive microgliosis results from stressed neurons secreting factors that
activate microglia, beginning the cycle of neuroinflammation and neuronal damage underlying
neurodegenerative diseases (4, 42, 45). Although neuroinflammation was not originally defined in the MitoPark
model, we show here that reactive microgliosis is likely involved, implicating an important therapeutic potential
for MTA and anti-inflammatory drugs in PD. This finding is salient considering that chronic neuroinflammation is
now perceived to mediate PD pathogenesis and current drugs only provide symptomatic relief (60, 66).
By restricting p47phox from translocating to the membrane and subsequently inhibiting superoxide production by
NOX2 in microglia, Mito-apo reduced inflammation in addition to its role as an antioxidant in neurons. This
combined effect on both microglia and neurons may help to break up a self-propelling cycle of
neuroinflammation and neurodegeneration characteristic of PD. This approach was also recently found to be
effective in the toxin-based MPTP model (28). It should be noted that the severity of the MitoPark model
allowed for only a modest recovery of motor function with Mito-apo treatment due to the complex nature of
the neurodegenerative process. We explored the potential benefit of a higher dose by performing a dose–
response study at the time point with the highest concentration of Mito-apo in the brain (Supplementary Fig.
S3D). However, our results did not show significantly more Mito-apo detectable in brain tissues of the 30 mg/kg
group versus 10 mg/kg group. This suggests that even at a higher dose, Mito-apo would not have provided an
additional benefit. Additional analysis of Mito-apo by LC-MS/MS did not detect the compound, but spiking the
samples with 0.1 μM concentration detected the peak. A detailed pharmacokinetic analysis of Mito-apo is still
warranted. Although oxidative stress and neuroinflammation are key players in the cell death mechanisms
leading to PD, other mechanisms such as protein aggregation, ubiquitin–proteasome system dysfunction,
mitophagy, and inflammasome-dependent neuroinflammation have not yet been fully addressed in this model
or with this compound. Furthermore, our group and others have shown that targeting a single
pathophysiological pathway is not typically enough to completely restore function in the MitoPark model
(24, 41). These observations warrant future studies into the therapeutic role of Mito-apo and the development
of combination therapy modalities for PD.

Recently, we have demonstrated that Mito-apo prevents hyposmia and motor deficits in the LRRK2 mouse
model (19). However, the effect of Mito-apo on mitochondrial function, microglial activation, NOX2 activation,
and dopaminergic degeneration was not directly investigated in that model. Although circadian and cognitive
changes occur in MitoPark mice (25, 43), the nonmotor Parkinsonian phenotype of these mice still needs to be
fully characterized. Moreover, Mito-apo efficacy in treating nonmotor symptoms in PD animal models should be
evaluated since antioxidants have been shown to successfully improve cognitive and neuropsychiatric symptoms
in various neurodegenerative models (64, 67).
Based on our findings using a progressively degenerating and mitochondrially dysfunctional animal model of PD,
Mito-apo may outperform other experimental drugs by being well tolerated yet bioavailable in the brain when
delivered orally, and by exhibiting potent antineuroinflammatory and antioxidant effects at a low dose. Here we
have demonstrated that Mito-apo protected dopaminergic neurons and reduced oxidative and nitrative stress,
glial cell activation, and inflammatory reactions. NOX2-mediated superoxide production is thought to be
essential for maintaining chronic neuroinflammation, which potentiates the neurodegenerative process through
oxidative stress (9, 52). NOX2 knockout or treatment with NOX2 inhibitors in cell culture and mouse studies
suggests that inhibiting NOX2 breaks the vicious, self-propelling cycle of reactive microgliosis, making it a
valuable target for PD therapy (61, 70). These properties strongly support potential clinical applications for Mitoapo as a viable neuroprotective and antineuroinflammatory drug for treating PD when compared to
conventional therapeutic approaches that only target downstream consequences of microglia activation and
inflammation-mediated oxidative stress. Overall, we demonstrate that Mito-apo treatment effectively
attenuates progressive motor deficits, neuroinflammation, neurochemical depletion, and loss of nigral TH
neurons, revealing a neuroprotective effect in a comprehensive PD model that recapitulates salient features of
chronic progressive dopaminergic neurodegeneration. Our proof-of-principle preclinical study warrants further
translation of Mito-apo to preclinical safety evaluations and to subsequent clinical testing.

Materials and Methods
Chemicals
Rotenone (R8875), oligomycin (75351), antimycin A (A8674), dopamine hydrochloride (H8502), 3-4dihydroxyphenylacetic acid (DOPAC, 850217), homovanillic acid (HVA, H1252), 3,3′-diaminobenzidine (DAB,
D5637), Griess reagent (4410), puromycin (P8833), and hydrogen peroxide (H325) were all purchased from
Sigma (St. Louis, MO). The CellTiter-Glo Cell Viability assay kit (G5421) was bought from Promega (Madison, WI).
We purchased RPMI 1640 (11875093), Dulbecco's modified Eagle's medium (DMEM) (11330), fetal bovine serum
(FBS, 26140), l-glutamine (25030081), penicillin–streptomycin (15140122), MitoTracker red (M-7512), and
MitoSOX (M36008) from Invitrogen (Carlsbad, CA), and the Seahorse Flux Pak calibration solution and
carbonilcyanide p-trifluoromethoxyphenylhydrazone (FCCP) (103015) from Seahorse Biosciences (Billerica, MA).
The aconitase assay kit (ab83459), anti-4-HNE (mab3249), anti-IBA1 (ab5076), and gp91phox (ab129068)
antibodies were purchased from Abcam (Cambridge, MA). Anti-NOS2 (sc-650) and p47phox (H-195) antibodies
were obtained from Santa Cruz Biotech (Dallas, TX), anti-IBA1 antibody (019-19741) was purchased from Wako
(Richmond, VA), and anti-TH (mab318) and anti-3-NT (06-284) antibodies were purchased from Millipore
(Billerica, MA).

Mito-apocynin synthesis
Mito-apo-C2 and Mito-apo-C11 were synthesized as described previously (19). Briefly, acetylvanillic acid and
thionyl chloride were mixed to form acetylvanillic acid chloride, which was dissolved in dichloromethane and
amino alkyl triphenyl phosphonium bromide and pyridine. The solution was purified on a silica gel column and
the acetyl group was removed by hydrolysis.

Cell culture and CRISPR/Cas-based knockout of TFAM in N27 cells
For in vitro mitochondrial function studies, the rat immortalized mesencephalic dopaminergic neuronal cell line
(1RB3AN27 or N27) was cultured in RPMI 1640 containing 2 mM l-glutamine, 50 U of penicillin, and 50 μg/ml of
streptomycin with 0–10% FBS in incubators at 37°C and 5% CO2 as previously described by our laboratory (8).
The lentivirus-based CRISPR/Cas9 KO plasmid, pLV-U6gRNA-Ef1aPuroCas9GFP-TFAM, with the TFAM gRNA
target sequence directed against the exon 1 sequence (CPR555e5e4099bf84.98), was purchased from SigmaAldrich. To make lentivirus, the lenti-CRISPR/Cas9 TFAM KO plasmid and control plasmid were transfected into
293FT cells using the Mission Lentiviral Packaging Mix (SHP001; Sigma-Aldrich) according to the manufacturer's
instructions. The lentivirus was harvested 48 h post-transfection and titers were measured using the Lenti-X™
p24 Rapid Titer Kit (632200; Clontech, Mountain View, CA). For stable KD of TFAM in N27 cells, six-well plates
containing 0.1 × 106/well had lentivirus added the following morning to the media at an MOI of 100. After 24 h,
fresh media supplemented with puromycin (50 μg/ml) was added to the cells for stable cell selection.
The wild-type microglial cell line, obtained as a kind gift from Dr. Golenbock at the University of Massachusetts,
was used for neuroinflammation experiments and cultured in DMEM containing 2 mM l-glutamine, 50 U of
penicillin, and 50 μg/ml of streptomycin with 2% FBS in six-well plates at a density of 1.5 × 106/well. The cell line
was immortalized from wild-type C57 mouse primary microglia by infection with J2 recombinant retrovirus
microglia and has been characterized by Halle et al. (37).

Mitochondrial oxygen consumption
The Seahorse XF96 analyzer was used to monitor basal OCR in N27 dopaminergic neuronal cells at different
stages as previously described (8). Briefly, after pre-equilibrating the cartridge containing the mito-stressors
oligomycin (1 μg/ml), FCCP (1 μM), and antimycin A (10 μM) in injection ports, a plate with cells pretreated in
serum-free media for 3 h with 0, 10, or 30 μM Mito-apo-C2 and 1 μM rotenone was placed into the Seahorse
analyzer. OCR readouts were measured in pmol/min.

Cell viability, aconitase, and NOX2 activity
The CellTiter-Glo Luminescent Cell Viability (used to measure intracellular ATP levels) and aconitase activity
assays were performed as per the manufacturer's instructions using control and TFAM stable KD N27 cells or
microglia. The CellTiter-Glo Luminescent Cell Viability assays were performed using control or TFAM stable KD
N27 cells (0.8 × 104/well) in a white opaque-walled 96-well plate.
For the aconitase activity assay, 1 × 106 cells were plated in a T25 flask. After treatments, mitochondrial fractions
were collected and lysed as per the manufacturer's instructions. Readings at 450 nm were obtained using a
SpectraMax plate reader and normalized to protein concentrations determined by Bradford assay.
NADPH oxidase activity was determined in differentiated human acute promyelocytic leukemia (dHL60) cells, as
recently reported (73, 75). Hydropropidine probe (20 μM), in the presence of DNA (0.1 mg/ml), was used to
monitor superoxide production, while coumarin boronic acid (100 μM) was used to monitor H2O2 formation.
HL60 cells were maintained and differentiated with ATRA (1 μM) for 5 days as described previously (73). The
differentiated cells were pretreated with Mito-apo for 30 min in HBSS supplemented with HEPES buffer (25 mM,
pH 7.4) and DTPA (0.1 mM), followed by the addition of the probe and PMA (1 μM). Immediately after addition
of PMA, the plates were placed in the plate reader and fluorescence intensity monitored over 2 h. The slope of
the fluorescence intensity over time was used to measure the probe oxidation rate. The rate of probe oxidation
in samples treated with pure DMSO (0.1% vol/vol) was taken as 100%.

Oxidation of mitochondrial boronate probe
Mitochondria-targeted boronates were proposed for site-specific detection of mitochondrial H2O2 (10, 11). For
adjusting the results for differential uptake/availability of the probe in mitochondria, the use of a ratio of the
phenolic product to probe level was proposed (10, 11). The o-MitoPhB(OH)2 probe (74, 75) was incubated with
microglial cells (50 μM, 1 h) before collecting the cells. The samples were prepared and analyzed by LC-MS/MS
using the deuterated analogs d15-MitoPhB(OH)2 and d15-MitoPhOH as the internal standards, as described
recently (74, 75).

MitoTracker and MitoSOX
N27 dopaminergic cells grown on poly-d-lysine-coated glass coverslips in 24-well plates were treated in 2% FBS
media for 12 h with 0, 10, or 30 μM Mito-apo-C2 or 1 μM rotenone, and then washed twice with PBS. CMXRos
MitoTracker Red dye (working concentration of 200 nM) was incubated at 37°C for 12 min. ImageJ was used to
quantify mitochondrial parameters as described previously (8, 14). MitoSOX reagent (working concentration of
5 μM) was used to detect mitochondrial oxidant(s) production in live N27 cells as per the manufacturer's
instructions. It should be noted that MitoSOX fluorescence does not allow for identification of the specific type
of oxidant(s) detected.

Nitric oxide and cytokine detection
Microglia were cotreated for 12 h with 1 μg/ml LPS and 0, 10, or 30 μM Mito-apo-C11. Supernatant was used to
determine extracellular cytokine levels using the Luminex bead-based immunoassay with recombinant
standards for IL-6, IL-12, TNF-α, and IL-1β. Nitric oxide production was measured as media nitrite levels using
Griess reagent and sodium nitrite standard curve as previously described (35).

Animals and treatments
MitoPark mice were a kind gift of Dr. Nils-Goran Larson at the Max Planck Institute for Biology and Ageing in
Cologne, Germany. All mice for this study were bred and housed under standard conditions (ad libitum food, a
12-h light cycle, constant temperature and humidity) at the Iowa State University (ISU) as approved by the
Institutional Animal Care and Use Committee. MitoPark and age-matched control mice were oral gavaged with
either 10 mg/kg Mito-apo-C11 dissolved in 10% ethanol in PBS or an equivolume vehicle solution thrice weekly
from age 13 to 24 weeks. Mice were subjected to behavioral testing, and neurochemical and histological
measurements were performed at age 24 weeks.

Behavior
Open-field and rotarod experiments were performed as previously described (32). Briefly, open-field
measurements of spontaneous locomotor activity were accomplished using VersaMax (monitor RXYZCM-16,
analyzer VMAUSB; AccuScan, Columbus, OH) during a 10-min acquisition period following a 2-min
accustomization. Coordination was assessed by rotarod (AccuScan) performance at 20 rpm for five trials not
exceeding 20 min.

HPLC analysis of neurotransmitters
Striatal lysates were prepared in an antioxidant buffer containing 0.2 M perchloric acid, 0.1% Na2S2O5, 0.05%
NaEDTA, and isoproterenol as an internal standard as previously described (33). Samples were sonicated for
2 min, centrifuged for 10 min, and filtered through a 0.2 μm filter before running. Samples were placed into an
autosampler (WPS-3000TSL; Thermo Scientific) at 4°C and separated isocratically by a reversed-phase C18
column at 0.6 ml/min (pump, Ultimate 3000 ISO-3100SD). Electrochemical detection (CoulArray 5600A) was
performed using potentials of 350, 0, −150, and 220 mV (microdialysis cell 5014B, guard cell 5020) to detect

dopamine, DOPAC, and HVA. Chromatograph integration and analyses were performed using Chromeleon
(7.1.3) and ESA CoulArray (3.10) software.

Western blotting
Western blot lysates from the striatum and SN were prepared in RIPA buffer with protease and phosphatase
inhibitors (Pierce Biotechnology) and run on a 10–15% sodium dodecyl sulfate/polyacrylamide gel
electrophoresis (SDS-PAGE) as previously described (33). Following SDS-PAGE electrophoresis, proteins were
transferred to a nitrocellulose membrane (Bio-Rad). After blocking for 1 h in LiCor blocking buffer or milk,
primary antibodies including 4-HNE (1:2000), TH (1:1500), iNOS (1:500), IBA1 (1:1200), and β-actin (1:7000) were
incubated at 4°C overnight. Secondary antibodies (Alexa Fluor 680 and Rockland IR800) were incubated at RT for
1 h and images were captured via LiCor Odyssey imager. Densitometric analysis was done using ImageJ software.

IHC and confocal imaging
Perfusion, sectioning, and IHC were performed as previously described by Ghosh et al. (33). Animals were
transcardially perfused with PBS and 4% PFA. The next day, brains were cryoprotected with 30% sucrose and
brain blocks were made in OCT. Cryo-solution containing ethylene glycol and sucrose was used to store 30-μm
sections until use. Following washing, antigen retrieval was achieved by keeping sections at 80°C for 30 min in
sodium citrate. Sections were incubated with primary antibodies overnight at 4°C. Appropriate secondary
antibodies (Alexa Fluor 488 and 555) were incubated with sections for 1.5 h, followed by 7 min with Hoechst
stain. Dehydrated slides were mounted using DPX.
Images (20–30 × ) were captured with an inverted microscope attached to a SPOT digital camera. For confocal
imaging, the ISU Microscopy Facility's Leica DMIRE2 confocal microscope was used to acquire 63 × z-stack
images, which were converted to maximum projection images using Imaris software.

DAB immunostaining and cell counting
For DAB staining, IHC was performed on 30-μm SN sections. A biotinylated secondary antibody followed by
incubation with an avidin peroxidase solution (Vector labs) was used to yield a brown stain after incubation with
DAB solution. Stereological counting of TH+ neurons was done on every sixth section at 40 × using Stereo
Investigator software (MicroBrightField) with an optical fractionator. Images (20 × ) for IBA1+ microglia analysis
were acquired with Spot software. ImageJ software was used to count microglial cells, adjust threshold, convert
images to binary, skeletonize, and analyze skeleton (49).

Electron paramagnetic resonance
EPR spectra were recorded on a Bruker ELEXSYS E600 spectrometer equipped with a Super-X microwave bridge
with an integrated microwave counter, an ER4112SHQ resonant cavity operating at 9.38 GHz, and an Oxford
Instruments ESR900 helium flow cryostat with an ITC503 temperature controller. Spectra were recorded at 12 K
with 5 mW microwave power and 10 G magnetic field modulation at 100 kHz; this modulation amplitude
determined the spectral resolution. Scans of 4096 points, an 8000 G field envelope, and a 3-min duration were
averaged over 60–180 min to provide the final spectrum. A background spectrum collected on frozen water was
subtracted from experimental spectra. Contributions of each of the paramagnetic centers of the mitochondrial
proteins to the experimental spectra were estimated by fitting a library of computed spectra corresponding to
the mitochondrial respiratory chain centers and the [3Fe–4S] cluster of aconitase, using a Levenberg–Marquardt
algorithm to minimize χ2 (IGOR Pro v. 6.32A; Wavemetrics, Lake Oswego, OR). The contributions of each
component were constrained to ≥0. Computed spectra of the individual components were calculated, using spin
Hamiltonian parameters from the literature (23, 26, 36, 40, 50, 58, 72), with XSophe [Bruker Biospin; (38)].

Detection of Mito-apo-C11 in brain and blood
Mice were administered 10 mg/kg Mito-apo-C11 by oral gavage and then sacrificed at 30 min, 3, 6, 12, 24, or
48 h (n = 3/time point). Blood was collected by cardiac puncture into heparinized tubes for plasma, and various
brain regions were dissected out and stored at −80°C. Tissue homogenates were then made using antioxidant
buffer, as described above for neurotransmitter extraction. The standards prepared and used for quantification
were 0.1, 0.3, 1.0, 10, and 30 μg. Samples were centrifuged and 0.2-μm filtered before analysis on an Agilent
Technologies 1200 Series HPLC system using a 20 -μl injection volume. Separation was performed with a Kinetex
C18 column, operated at a flow rate of 1.5 ml/min and a temperature of 40°C, using a gradient elution (solvent
A = 90% water, 10% acetonitrile, solvent B = 100% acetonitrile) over 10 min. Mito-apo-C11 was quantified by UV
absorbance (collected at wavelengths of 262 and 292 nm) with an average retention time of 6.35 min. Standards
were fit to a linear regression and data were analyzed using GraphPad Prism 4.0.

Statistical analysis
Data were analyzed by one-way analysis of variance with Bonferroni post-test using Prism 4.0 software.
Differences with p-values ≤0.05 were considered significant.
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Abbreviations Used
4-HNE
6-OHDA
ALP
ATRA
CBA
CNS
CRISPR
DA
DMEM
l-DOPA
DOPAC
EPR
FBS
FCCP
HPLC
HPr+
HVA
IBA1
iNOS
IL
KD
LPS

4-hydroxynonenal
6-hydroxydopamine
alkaline phosphatase
all-trans retinoic acid
coumarin boronic acid
central nervous system
clustered regularly interspaced short palindromic repeats
dopamine
Dulbecco's modified Eagle's medium
l-3,4-dihydroxyphenylalanine
3,4-dihydroxyphenylacetic acid
electron paramagnetic resonance
fetal bovine serum
carbonilcyanide p-trifluoromethoxyphenylhydrazone
high-performance liquid chromatography
hydropropidine
homovanillic acid
ionized calcium-binding adapter molecule 1
inducible nitric oxide synthase
interleukin
knockdown
lipopolysaccharide

LRRK2
Mito-apo
MP
MPTP
MTA
NOX
OCR
PD
PINK1
PMA
ROS
SN
TFAM
TH
TNFα

leucine-rich repeat kinase 2
Mito-apocynin
MitoPark
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
mitochondria-targeted antioxidants
NADPH oxidase
oxygen consumption rate
Parkinson's disease
PTEN-induced putative kinase 1
phorbol myristate acetate
reactive oxygen species
substantia nigra
mitochondrial transcription factor A
tyrosine hydroxylase
Tumor necrosis factor α
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